时间依赖性扩散MRI有助于预测乳腺癌分子亚型及新辅助化疗治疗反应
该前瞻性研究纳入408例浸润性乳腺癌患者,采用IMPULSED方法的时间依赖性扩散MRI进行微结构映射,评估其预测分子亚型和新辅助化疗后病理完全缓解(pCR)的价值。结果显示,该方法对HER2富集型乳腺癌预测AUC达0.85,优于ADC测量(均P<.05);联合模型预测pCR的AUC为0.88,优于ADC测量和临床-病理模型(AUC分别为0.73和0.79,P<.001)。
要点
- 时间依赖性扩散MRI对HER2富集型乳腺癌识别AUC为0.85,优于ADC测量(均P<.05)。
- 联合模型预测新辅助化疗后pCR的AUC为0.88,优于ADC测量和临床-病理模型。
- 孕激素受体状态、HER2状态和细胞密度指数与新辅助化疗后pCR独立相关。
核心结论
- 基于时间依赖性扩散MRI的微结构映射是帮助预测乳腺癌分子亚型和新辅助化疗后pCR的有效方法。
研究设计与样本
- 前瞻性研究,纳入2021年2月至2023年5月期间接受治疗前时间依赖性扩散MRI的浸润性乳腺癌患者408例(平均年龄51.9岁±9.1[SD]),采用IMPULSED方法估算4个微结构参数,并与3个ADC测量值和1个相对ADC扩散加权成像参数进行比较。
关键影像表现/征象
- 时间依赖性扩散MRI参数在帮助识别Luminal A型(AUC为0.70)、Luminal B型(AUC为0.78)和三阴性乳腺癌亚型(AUC为0.72)方面表现出合理性能。
- 时间依赖性扩散MRI参数对HER2富集型乳腺癌识别表现出高性能(AUC为0.85),优于ADC测量(均P<.05)。
- 时间依赖性扩散MRI估算参数与病理学测量相关性良好(n=100;r=0.67-0.81;P<.001)。
诊断标准与关键数值
- 时间依赖性扩散MRI预测Luminal A型乳腺癌的AUC为0.70。
- 时间依赖性扩散MRI预测Luminal B型乳腺癌的AUC为0.78。
- 时间依赖性扩散MRI预测三阴性乳腺癌的AUC为0.72。
- 时间依赖性扩散MRI预测HER2富集型乳腺癌的AUC为0.85,优于ADC测量(均P<.05)。
- 联合模型预测pCR的AUC为0.88,优于ADC测量(AUC为0.73)和临床-病理模型(AUC为0.79)(P<.001)。
临床应用与阅片要点
- 孕激素受体状态(OR为0.08;P=.02)、HER2状态(OR为3.36;P=.009)和细胞密度指数(OR为0.01;P=.02)与新辅助化疗后pCR的 odds 独立相关。
- 时间依赖性扩散MRI参数与病理学测量相关性良好(n=100;r=0.67-0.81;P<.001),可用于无创预测乳腺癌分子亚型和新辅助化疗后pCR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Time-dependent diffusion MRI has the potential to help characterize tumor cell properties; however, to the knowledge of the authors, its usefulness for breast cancer diagnosis and prognostic evaluation is unknown. Purpose To investigate the clinical value of time-dependent diffusion MRI-based microstructural mapping for noninvasive prediction of molecular subtypes and pathologic complete response (pCR) in participants with breast cancer. Materials and Methods Participants with invasive breast cancer who underwent pretreatment with time-dependent diffusion MRI between February 2021 and May 2023 were prospectively enrolled. Four microstructural parameters were estimated using the IMPULSED method (a form of time-dependent diffusion MRI), along with three apparent diffusion coefficient (ADC) measurements and a relative ADC diffusion-weighted imaging parameter. Multivariable logistic regression analysis was used to identify parameters associated with each molecular subtype and pCR. A predictive model based on associated parameters was constructed, and its performance was assessed using the area under the receiver operating characteristic curve (AUC) and compared by using the DeLong test. The time-dependent diffusion MRI parameters were validated based on correlation with pathologic measurements. Results The analysis included 408 participants with breast cancer (mean age, 51.9 years ± 9.1 [SD]). Of these, 221 participants were administered neoadjuvant chemotherapy and 54 (24.4%) achieved pCR. The time-dependent diffusion MRI parameters showed reasonable performance in helping to identify luminal A (AUC, 0.70), luminal B (AUC, 0.78), and triple-negative breast cancer (AUC, 0.72) subtypes and high performance for human epidermal growth factor receptor 2 (HER2)-enriched breast cancer (AUC, 0.85), outperforming ADC measurements (all P < .05). Progesterone receptor status (odds ratio [OR], 0.08; P = .02), HER2 status (OR, 3.36; P = .009), and the cellularity index (OR, 0.01; P = .02) were independently associated with the odds of achieving pCR. The combined model showed high performance for predicting pCR (AUC, 0.88), outperforming ADC measurements and the clinical-pathologic model (AUC, 0.73 and 0.79, respectively; P < .001). The time-dependent diffusion MRI-estimated parameters correlated well with the pathologic measurements (n = 100; r = 0.67-0.81; P < .001). Conclusion Time-dependent diffusion MRI-based microstructural mapping was an effective method for helping to predict molecular subtypes and pCR to neoadjuvant chemotherapy in participants with breast cancer. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Partridge and Xu in this issue.
引用
- Wang X, Ba R, Huang Y, et al. Time-Dependent Diffusion MRI Helps Predict Molecular Subtypes and Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology. 2024. PMID: 39436292. doi:10.1148/radiol.240288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。